CNS & Neurological Disorders - Drug Targets
October 14, 2026
Sheekha Chaudhary, Sanchit Dhankhar, Monika Saini et al.
More than fifty million individuals worldwide are experiencing neurodegenerative disorders, which include Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and frontotemporal dementia. These disorders have a significant role in the gradual degradation of cognition and motor skills. Most current treatment approaches have little...
CNS & Neurological Disorders - Drug Targets
July 31, 2026
Sampriti Paul, Sonal Dubey, Mayur Yergeri Chandrasekharappa et al.
Recent advances in neuropsychopharmacology have renewed interest in psychedelics and entactogens as potential treatments for brain disorders, owing to their rapid effects on neural plasticity, cognition, and affect. Classical serotonergic psychedelics primarily act as 5-HT2A receptor agonists with additional activity at 5-HT1A and other serotonin receptors, whereas entactogens such as MDMA...
CNS & Neurological Disorders - Drug Targets
July 16, 2026
Tawqeer Shafi, Zora Singh, Puja Gulati et al.
INTRODUCTION: Zolpidem is a widely used non-benzodiazepine hypnotic that is used as a treatment for insomnia due to its rapid onset and perceived safety. Nevertheless, rising clinical reports and post-marketing surveillance have identified serious neuropsychiatric adverse effects, such as hallucinations, perceptual disturbances, and complex sleep-related behaviors, such as sleep-driving and...
CNS & Neurological Disorders - Drug Targets
March 18, 2026
Rajkapoor Balasubramanian, Naina Mohamed Pakkir Maideen, Krishnaveni Kandasamy et al.
Abstract: Nitrous oxide (N2O), known as laughing gas, is a colorless, low-volume gas that has become commonly used in busy maternity wards, emergency rooms, and dental offices. It provides an introduction to the principles and practices of anesthesia, sedation, and analgesia. This review examines the recreational use and prolonged exposure to nitrous oxide (N2O), both of which are associated...
CNS & Neurological Disorders - Drug Targets
March 11, 2026
Shikha Baghel Chauhan, Naziya Akhtar, Chirag Jain et al.
Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they activate intracellular cascades...
CNS & Neurological Disorders - Drug Targets
April 17, 2017
Giovanni Martinotti, Rita Santacroce, Duccio Papanti et al.
62 citations
BACKGROUND: Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. The short- and long- term health risks associated with the consumption of SC are often unknown to both users and health professionals. This review aims to provide a synthesis of the most recent and relevant insights on the pharmacology, clinical and psychopathological aspects of SC....
CNS & Neurological Disorders - Drug Targets
2017
Eric Murillo-Rodriguez, Jose Carlos Pastrana-Trejo, Mireille Salas-Crisóstomo et al.
Cannabinoids are derivatives that are either compounds occurring naturally in the plant, Cannabis sativa or synthetic analogs of these molecules. The first and most widely investigated of the cannabinoids is Δ9-tetrahydrocannabinol (Δ9-THC), which is the main psychotropic constituent of cannabis and undergoes significant binding to cannabinoid receptors. These cannabinoid receptors are...
CNS & Neurological Disorders - Drug Targets
2017
Gustavo Vazquez, Sebastian Camino, Leonardo Tondo et al.
Treatments for depression in bipolar disorder (BD) are far less well developed than for unipolar major depressive disorder. Several innovative and experimental approaches have been emerging recently, including use of the dissociative anesthetic ketamine and other antagonists of central NMDA glutamate receptors, as well as unsaturated fatty acids, anti-inflammatory agents, and possibly probiotic...
CNS & Neurological Disorders - Drug Targets
2017
Francesco P Busardò, Manuela Pellegrini, Julia Klein et al.
Delta (9)-tetrahydrocannabinol (THC) is the main psychoactive compound in cannabis and is frequently identified in blood samples from apprehended drivers suspected for driving under the influence of drugs. Changing social norms towards cannabis and higher acceptability towards the drug emphasize the need for in-depth understanding of the acute neurocognitive and psychomotor effects caused by...